|
|
|
|
| LEADER |
01943nam a22003615i 4500 |
| 001 |
000294131 |
| 005 |
20211014080753.0 |
| 007 |
cr nn 008mamaa |
| 008 |
130804s2013 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781461476542
|
| 024 |
7 |
|
|a 10.1007/978-1-4614-7654-2
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Resistance to Immunotherapeutic Antibodies in Cancer :
|b Strategies to Overcome Resistance /
|c edited by Benjamin Bonavida.
|
| 250 |
|
|
|a 1st ed. 2013.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2013.
|
| 300 |
|
|
|a XIII, 202 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|v 2
|
| 505 |
0 |
|
|a Preface -- Introduction and generation of chimeric and humanized mAbs -- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment -- Antibodies directed against different major cancers: Effects when used alone or in combination with drugs -- Mechanisms of antibodies-mediated responses, in vitro and in vivo -- Molecular Pathways -- Molecular Signatures -- Identification of resistance targets for intervention -- Various chemicals that can sensitize resistant tumor cells -- Other mAbs -- Proteasome inhibitors -- Divalent mAbs -- Antibodies coupled to chemical inhibitors -- Antibodies coupled to cytokines -- Nanoparticles with mAbs -- Index.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Molecular biology.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Antibodies.
|
| 650 |
1 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Molecular Medicine.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Antibodies.
|
| 700 |
1 |
|
|a Bonavida, Benjamin.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 900 |
|
|
|a Libro descargado a ALEPH en bloque (proveniente de proveedor)
|